Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China; Laboratory of Brain Disorders, Capital Medical University, Beijing, China; Ministry of Science and Technology, Capital Medical University, Beijing, China; Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China; Advanced Innovation Center for Big Data-Based Precision Medicine, Capital Medical University, Beijing, China; Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Cancer Lett. 2021 May 28;506:83-94. doi: 10.1016/j.canlet.2021.02.021. Epub 2021 Mar 4.
Glioma stem cells (GSCs) are thought to underlie glioma initiation, evolution, resistance to therapies, and relapse. They are defined by their capacity to initiate glioma in immunocompromised mice which precludes analysis of their interaction with immune cells. Macrophages dominate the immune cell composition in glioma. We hypothesized that stemness and immune evasion induced by macrophages are closed intertwined in glioma. By using mass cytometry and RNA sequencing, we reveal that in immunocompetent mice, FGL2 promotes the stem-like phenotypes of glioma cells in an expression level-dependent manner. Mechanistically, FGL2-producing glioma cells recruit macrophages into the tumor microenvironment and induce the macrophages to secrete CXCL7 via the CD16/SyK/PI3K/HIF1α pathways. CXCL7, in turn, enhances the stem-like functionality of glioma cells, resulting in an increase in tumor incidence and progression that can be blocked with a neutralizing anti-CXCL7 antibody. Clinically, the FGL2-CXCL7 paracrine loop positively correlated with a higher macrophage signature and poorer prognosis in glioma patients. Thus, glioma cells' stem-like functionality is regulated by FGL2 in the presence of macrophages, and the FGL2-CXCL7 paracrine signaling axis is critical for regulating this function.
神经胶质瘤干细胞(GSCs)被认为是神经胶质瘤发生、演变、对治疗的抵抗和复发的基础。它们的特征是能够在免疫功能低下的小鼠中引发神经胶质瘤,这排除了对其与免疫细胞相互作用的分析。巨噬细胞在神经胶质瘤中占据了免疫细胞组成的主导地位。我们假设巨噬细胞诱导的干性和免疫逃避在神经胶质瘤中是紧密交织在一起的。通过使用质谱流式细胞术和 RNA 测序,我们揭示了在免疫活性小鼠中,FGL2 以表达水平依赖的方式促进神经胶质瘤细胞的干性表型。在机制上,产生 FGL2 的神经胶质瘤细胞招募巨噬细胞进入肿瘤微环境,并通过 CD16/SyK/PI3K/HIF1α 途径诱导巨噬细胞分泌 CXCL7。CXCL7 反过来增强了神经胶质瘤细胞的干性功能,导致肿瘤发生率和进展的增加,而用中和抗 CXCL7 抗体可以阻断这种增加。临床上,FGL2-CXCL7 旁分泌环与神经胶质瘤患者中更高的巨噬细胞特征和更差的预后呈正相关。因此,在巨噬细胞存在的情况下,神经胶质瘤细胞的干性功能受 FGL2 调节,而 FGL2-CXCL7 旁分泌信号轴对于调节这种功能至关重要。